Eli Lilly & Co, treatment with your JAK inhibitor baricitinib has proven to be a life saving and altering treatment for children and adults living with the debilitating neuroinflammatory brain disease Aicardi-Goutieres Syndrome (AGS). For reasons unknown, our community has waited without update for you to continue advocating for approval with the FDA. In the interim, AGS families around the world have struggled with cost and access issues despite compelling testimonials, published evidence of safety and efficacy, and the support and advocacy of the American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR).
Engage in dialogue and partner with the community and patient advocacy group, the AGSAA.
Provide cost assistance to AGS families.
Advocate for approval with the FDA.
AGS Families and Supporters, join us and advocate for better access to baricitinib. Share your testimonials and sign our petition. Be heard!